Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

68.71USD
10:47pm IST
Change (% chg)

$-0.36 (-0.52%)
Prev Close
$69.07
Open
$69.58
Day's High
$69.58
Day's Low
$68.27
Volume
795,140
Avg. Vol
851,063
52-wk High
$72.31
52-wk Low
$47.37

TEVA.N

Chart for TEVA.N

About

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. The Company's generic products cover almost every major therapeutic area. The Company operates its business in two segments: Generic medicines, which manufactures and sells generic pharmaceutical products in several dosage forms, including... (more)

Overall

Beta: 0.66
Market Cap(Mil.): $67,219.38
Shares Outstanding(Mil.): 960.35
Dividend: 0.34
Yield (%): 1.95

Financials

  TEVA.N Industry Sector
P/E (TTM): 21.50 36.75 40.14
EPS (TTM): 3.21 -- --
ROI: 7.88 16.48 15.75
ROE: 12.09 17.28 16.79
Search Stocks

Healthcare deals lift July to 7th busiest M&A month on record

LONDON - A surge of takeover activity involving healthcare, financial and retail companies lifted the value of deals in July over $430 billion, making it the seventh-busiest mergers and acquisition month on record, Thomson Reuters data showed.

4:38pm IST

Teva's MS drug Copaxone has strong second-quarter sales

JERUSALEM - Teva Pharmaceutical Industries , which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition.

30 Jul 2015

Teva's MS drug Copaxone has strong second-quarter sales

JERUSALEM, July 30 - Teva Pharmaceutical Industries, which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition.

30 Jul 2015

RPT-Mylan independence from Teva's embrace comes with a price

July 27 - Generic drugmaker Mylan NV won a reprieve on Monday from its unwanted suitor, Teva Pharmaceutical Industries, but now faces an uphill battle to make its own acquisition as its biggest rival just got bigger.

28 Jul 2015

PRESS DIGEST- Wall Street Journal - July 28

July 28 - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

28 Jul 2015

Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid

TEL AVIV - Israel’s Teva Pharmaceutical Industries will pay $40.5 billion in cash and stock for Allergan’s generic drugs business, solidifying Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs, paying down debt and potential "transformational" acquisitions. | Video

28 Jul 2015

Mylan independence from Teva's embrace comes with a price

- Generic drugmaker Mylan NV won a reprieve on Monday from its unwanted suitor, Teva Pharmaceutical Industries, but now faces an uphill battle to make its own acquisition as its biggest rival just got bigger.

28 Jul 2015

Mylan independence from Teva's embrace comes with a price

July 27 - Generic drugmaker Mylan NV won a reprieve on Monday from its unwanted suitor, Teva Pharmaceutical Industries, but now faces an uphill battle to make its own acquisition as its biggest rival just got bigger.

28 Jul 2015

Allergan CEO, fresh off one deal, sets sights on others

NEW YORK - Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.

28 Jul 2015

UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bid

* Combined entity to have proforma revenue of $26 bln in 2016

28 Jul 2015

Competitors

  Price Chg
Novartis AG (NOVN.VX) CHF100.40 +0.40
Biogen Inc (BIIB.OQ) $320.96 +3.96

Earnings vs. Estimates

Search Stocks